● Constellation Pharmaceuticals was acquired by MorphoSys in July 2021 and is now part of Novartis● Co-led a difficult-to-drug oncology target through HTS campaign that identified two structurally enabled chemical series● Identified CROs and managed productive relationships with their pharmacology and chemistry teams to characterize hits and advance SAR, respectively● Simultaneously co-led a novel epigenetic target at the hit finding stage

● Kintai Therapeutics restructured and became Senda Biosciences in 2020● Led chemistry team focused on identifying microbiome-inspired therapeutics for Parkinson's Disease● Provided chemistry guidance to drive internal exploratory projects and an early external partnership

● Led team that discovered bifunctional Protacs in two distinct chemical series that degraded a protein of interest for an immuno-oncology project● Conceived of and led chemistry effort on a fragment-based screen for a challenging antibacterial program. Led to the discovery of a therapeutic target and accompanying chemical matter

● Responsible for new target identification and validation, identification of tool molecules for early programs, and hit-to-lead efforts to generate in vivo-ready chemical matter● Developed a "gut only" tool molecule to investigate tissue-specific activation of a target leading to a clear decision to terminate the program ● Led SAR activities resulting in orally bioavailable analogues that act on ion channel target for in vivo proof of biology studies● Identified a replacement chemotype from an HTS campaign for a cardiovascular target that had proven resistant to discovery of new chemical matter

● Focused on identification of selective kinase inhibitors for non-oncology indications● Worked up a screening campaign to discover an aminopyrazole chemotype that exhibits a unique binding mode to IRAK4● Used structure-based drug design to progress the hit to a selective and bioavailable inhibitor that was used to validate the program's cellular and in vivo PD assays● Our efforts led to discovery of an orally bioavailable IRAK4 inhibitor that was efficacious in a mouse model of inflammation

● Responsible for the design and synthesis of biologically active molecules for CNS targets● Pioneered heteroaryl replacements for alicycles for PDE10A inhibitor program. These findings led to discovery of an analogue with both activity in rodent model of disease and cynomolgus exposure